Acta Diabetologica

, Volume 45, Issue 3, pp 143–145 | Cite as

Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver

  • Paolo Tessari
  • Antonio Tiengo
Original Article


Metformin has been proposed as a potential drug treatment to reduce liver steatosis. Therefore, the study of the effects of in vivo metformin administration, on hepatic fat metabolism in the isolated perfused liver is of great interest. We have studied the effects of in vivo metformin treatment of rats with experimentally induced overweight, hyperglycemia and hypertriglyceridemia, on plasma hormone and metabolite concentrations, as well as on triglyceride and ketone body output by the isolated perfused livers. Sprague–Dawley rats were fed ad libitum with a high lipid diet for 10 weeks. Then, one rat group was treated for 7 days with 350 μg/kg of BW of metformin per day, whereas the control group received only water. Thereafter, the livers were excised and perfused in vitro under controlled conditions. The hypertriglyceridemic rats had a greater body weight, as well as greater plasma glucose, insulin and triglyceride concentrations, than the control rats fed ordinary chow. In vivo metformin treatment decreased plasma glucose, insulin and triglyceride concentrations. With respect to the overweight, hyperglycemic, hypertriglyceridemic, untreated control rats, the cumulative (i.e. over 3 h of perfusion) triglyceride output by the perfused livers was decreased by >60%, whereas total ketone body (i.e. the sum of 3-hydroxybutyrate and acetoacetate) output was increased by >100% (p < 0.01 for both). In conclusion, the in vivo treatment with metformin of rats with diet-induced overweight and hypertriglyceridemia is capable to re-address hepatic fatty acid metabolism from lipogenesis toward fat oxidation and ketone body production, either directly or through a reduction of insulin concentrations.


Metformin Perfused liver Ketones Triglycerides 


  1. 1.
    Angulo P (2002) Non-alcoholic fatty liver disease. N Engl J Med 346:1221–1231PubMedCrossRefGoogle Scholar
  2. 2.
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Non-alcoholic fatty liver, steatohepatitis and the metabolic sindrome. Hepatology 37:917–923PubMedCrossRefGoogle Scholar
  3. 3.
    Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G (2005) Randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100(5):1082–1090PubMedCrossRefGoogle Scholar
  4. 4.
    Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998–1003PubMedCrossRefGoogle Scholar
  5. 5.
    Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152PubMedGoogle Scholar
  6. 6.
    Nosadini R, Ursini F, Tessari P, De Biasi F, Tiengo A (1979) Hormonal and metabolic characteristics of genetically obese and dietary obese Sprague–Dawley rats. Eur J Clin Invest 10:113–118CrossRefGoogle Scholar
  7. 7.
    Miller LL (1973) Technique of isolated rat liver perfusion. In: Bartosek I, Guaitani A, Miller LL (eds) Isolated liver perfusion and its application. Raven Press, New York, pp 11–53Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Clinical and Experimental Medicine, Chair of MetabolismUniversity of PaduaPaduaItaly

Personalised recommendations